EZH2 and cutaneous melanoma: Moreover, EZH2 was strongly expressed in some melanoma cell lines, and the treatment with EZH2 inhibitor GSK126 induced a reduction of H3K27me3, affecting the migratory capability of melanoma cells [9].Tumor cells may exert potent immunosuppressive activity but, despite this, the immune system has been shown to play a key role in the control of both in situ disease and tumor progression [10,11,12,13]; in this context, the presence of tumor-infiltrating lymphocytes has been suggested to predict the positivity of sentinel lymph node of cutaneous melanoma [14].